<p>根据 Allworth Financial LP 最近向 SEC 提交的 13F 表格，该公司在 2023 年第四季度将其在百时美施贵宝公司（NYSE:BMY - 免费报告）的持股增加了 106.4%。该公司在此期间额外购买了 111,973 股后，持有 217,248 股该生物制药公司的股票。Allworth Financial LP 在百时美施贵宝的持股在最近一个季度末的价值为 11,718,000 美元。</p>
<p>获取 <strong>百时美施贵宝</strong> 的提醒：</p>
<ul>
<li>2 只值得投资的巴菲特股票——以及 1 只需要抛弃的股票</li>
</ul>
<p>其他一些对冲基金也调整了对该公司的持股。先锋集团（Vanguard Group Inc.）在第四季度将其在百时美施贵宝的持股增加了 1.4%。先锋集团目前持有 198,727,768 股该生物制药公司的股票，价值 10,719,376,000 美元，此前在此期间额外购买了 2,743,759 股。道富银行（State Street Corp）在第三季度将其在百时美施贵宝的持股增加了 2.0%。道富银行目前持有 96,595,232 股该生物制药公司的股票，价值 4,356,445,000 美元，此前在此期间额外购买了 1,855,238 股。Dimensional Fund Advisors LP 在第三季度将其在百时美施贵宝的持股增加了 11.5%。Dimensional Fund Advisors LP 目前持有 18,143,672 股该生物制药公司的股票，价值 818,105,000 美元，此前在此期间额外购买了 1,873,618 股。Legal &amp; General Group Plc 在第三季度将其在百时美施贵宝的持股增加了 8.4%。Legal &amp; General Group Plc 目前持有 17,075,743 股该生物制药公司的股票，价值 770,116,000 美元，此前在此期间额外购买了 1,317,199 股。最后，Pzena Investment Management LLC 在第三季度将其在百时美施贵宝的持股增加了 0.4%。Pzena Investment Management LLC 目前持有 14,901,604 股该生物制药公司的股票，价值 672,062,000 美元，此前在上个季度额外购买了 58,129 股。76.41% 的股票由机构投资者和对冲基金持有。</p>
<h2>分析师设定新的价格目标</h2>
<p>BMY 近期成为多份研究报告的主题。Cantor Fitzgerald 将百时美施贵宝的目标价格从 45.00 美元上调至 54.00 美元，并在 4 月 8 日的研究报告中给予该股票 “中性” 评级。摩根士丹利在 2 月 6 日的研究报告中重申了 “减持” 评级，并对百时美施贵宝的股票设定了 40.00 美元的目标价格。汇丰银行在 3 月 17 日的研究报告中将百时美施贵宝的目标价格从 53.00 美元上调至 60.00 美元，并给予该股票 “持有” 评级。美国银行在 4 月 9 日的研究报告中将百时美施贵宝的目标价格从 68.00 美元下调至 67.00 美元，并对该股票设定了 “买入” 评级。最后，加拿大皇家银行在 2 月 24 日的研究报告中开始覆盖百时美施贵宝。他们给予该股票 “行业表现” 评级，并设定了 60.00 美元的目标价格。八位研究分析师对该股票给予了买入评级，十位给予了持有评级，一位给予了卖出评级。根据 MarketBeat.com 的数据，该公司的当前共识评级为 “持有”，平均目标价格为 61.31 美元。</p>
<ul>
<li>为什么 GRAIL 股票可能成为生物技术领域的下一个重大突破</li>
</ul>
<p><strong>查看我们对百时美施贵宝的最新股票分析</strong></p>
<h2>百时美施贵宝的内部交易</h2>
<p>在其他百时美施贵宝的新闻中，执行副总裁 David V. Elkins 在 4 月 1 日星期三出售了 30,000 股该股票。该股票以平均价格 61.67 美元出售，总交易额为 1,850,100.00 美元。交易后，该执行副总裁在公司持有 159,248 股，价值约为 9,820,824.16 美元。这代表了他们持股的 15.85% 的减少。该出售在向 SEC 提交的文件中披露，可以通过此超链接访问。公司内部人士持有该公司股票的 0.05%。</p>
<h2>百时美施贵宝股票表现</h2>
<ul>
<li>不要被反弹所迷惑：市场风暴尚未结束</li>
</ul>
<p>BMY 股票在周五开盘价为 56.76 美元。该公司的市值为 1159.1 亿美元，市盈率为 15.94，市盈增长比率为 0.16，贝塔值为 0.26。该公司的 50 日移动平均线为 58.74 美元，200 日移动平均线为 55.34 美元。该公司的流动比率为 1.42，速动比率为 1.28，债务与股本比率为 2.10。百时美施贵宝公司的 12 个月低点为 42.52 美元，12 个月高点为 62.89 美元。</p>
<p>百时美施贵宝（NYSE:BMY - 获取免费报告）最近在 4 月 30 日星期四发布了季度财报。该生物制药公司报告每股收益（EPS）为 1.58 美元，超出分析师的共识预期 1.42 美元，超出幅度为 0.16 美元。该公司在本季度的收入为 114.9 亿美元，而共识预期为 109.3 亿美元。百时美施贵宝的股本回报率为 64.87%，净利润率为 15.01%。百时美施贵宝本季度的收入同比增长 2.6%。在去年同期，该公司每股收益为 1.80 美元。百时美施贵宝已将其 2026 财年的指导目标设定为 6.050-6.350 EPS。分析师预计百时美施贵宝公司在当前财年将发布 6.3 EPS。</p>
<h2>百时美施贵宝宣布分红</h2>
<p>该公司最近还宣布了一项季度分红，该分红于 5 月 1 日星期五支付。4 月 2 日星期四的登记股东获得每股 0.63 美元的分红。除息日期为 4 月 2 日星期四。这代表了每年 2.52 美元的分红，收益率为 4.4%。百时美施贵宝的分红支付比率目前为 70.79%。</p>
<h2>百时美施贵宝简介</h2>
<p>（免费报告）</p>
<p>百时美施贵宝是一家全球生物制药公司，总部位于新泽西州普林斯顿，专注于发现、开发和提供针对严重疾病的药物。公司的核心业务包括在多个治疗领域进行处方药的研究与开发、临床开发、生产和商业化。百时美施贵宝专注于通过小分子和生物制剂推进肿瘤学、血液学、免疫学、心血管疾病和特殊领域的治疗。</p>
<p>百时美施贵宝的市场产品组合和后期管线反映出对癌症和免疫介导疾病的强烈关注。</p>
<h2>了解更多</h2>
<ul>
<li>五只我们认为比百时美施贵宝更好的股票</li>
<li>YETI 在财报超预期和上调前景后反弹</li>
<li>三家领先量子公司的第一季度财报对比</li>
<li>思科的垂直反弹可能仍处于早期阶段</li>
<li>亚马逊与阿里巴巴：现在显然更具价值的选择</li>
</ul>
<p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5ZU0UmU3ltYm9sPUJNWQ?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5ZU0UmU3ltYm9sPUJNWQ"/></p>
<p><em>此即时新闻提醒由叙事科学技术和来自 MarketBeat 的金融数据生成，以便为读者提供最快的报道和公正的覆盖。请将有关此故事的任何问题或评论发送至 contact@marketbeat.com。</em></p>
<h2>你现在应该投资 1,000 美元在百时美施贵宝吗？</h2>
<p>在考虑百时美施贵宝之前，你需要听听这个。</p>
<p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已识别出五只顶级分析师悄悄建议客户现在购买的股票，以便在更广泛的市场注意到之前……而百时美施贵宝并不在名单上。</p>
<p>虽然百时美施贵宝目前在分析师中被评为持有评级，但顶级分析师认为这五只股票更值得购买。</p>
<p>在这里查看这五只股票</p>

百时美施贵宝

标普生物技术 ETF - SPDR

生物科技 ETF - VanEck Vectors

纳斯达克生物科技指数 ETF - iShares Nasdaq

医药 3 倍做多 - Direxion

标普生物技术 3 倍做多 - Direxion

动态生物技术与基因组 ETF - Invesco

纽交所高增长板生物技术指数 ETF - First Trust

<p>Allworth Financial LP 在第四季度将其在百时美施贵宝（NYSE:BMY）的股份增加了 106.4%，目前持有 217,248 股，价值 1170 万美元。其他机构投资者也增加了他们的持股。分析师设定的目标价格范围为 40 美元至 68 美元，普遍评级为 “持有”，平均目标价格为 61.31 美元。该股票开盘价为 56.76 美元，市值为 1159.1 亿美元</p>

<p>Allworth Financial LP grew its position in Bristol Myers Squibb Company (NYSE:BMY - Free Report) by 106.4% during the fourth quarter, according to its most recent Form 13F filing with the SEC. The firm owned 217,248 shares of the biopharmaceutical company's stock after purchasing an additional 111,973 shares during the period. Allworth Financial LP's holdings in Bristol Myers Squibb were worth $11,718,000 at the end of the most recent quarter.</p>
<div class="lb-trans"><p>根据 Allworth Financial LP 最近向 SEC 提交的 13F 表格，该公司在 2023 年第四季度将其在百时美施贵宝公司（NYSE:BMY - 免费报告）的持股增加了 106.4%。该公司在此期间额外购买了 111,973 股后，持有 217,248 股该生物制药公司的股票。Allworth Financial LP 在百时美施贵宝的持股在最近一个季度末的价值为 11,718,000 美元。</p>
</div><p>Get <strong>Bristol Myers Squibb</strong> alerts:</p>
<div class="lb-trans"><p>获取 <strong>百时美施贵宝</strong> 的提醒：</p>
</div><ul>
<li>2 Buffett Stocks to Load Up On—And 1 to Ditch</li>
</ul>
<div class="lb-trans"><ul>
<li>2 只值得投资的巴菲特股票——以及 1 只需要抛弃的股票</li>
</ul>
</div><p>A number of other hedge funds have also modified their holdings of the company. Vanguard Group Inc. increased its holdings in shares of Bristol Myers Squibb by 1.4% in the fourth quarter. Vanguard Group Inc. now owns 198,727,768 shares of the biopharmaceutical company's stock valued at $10,719,376,000 after purchasing an additional 2,743,759 shares during the period. State Street Corp increased its holdings in shares of Bristol Myers Squibb by 2.0% in the third quarter. State Street Corp now owns 96,595,232 shares of the biopharmaceutical company's stock valued at $4,356,445,000 after purchasing an additional 1,855,238 shares during the period. Dimensional Fund Advisors LP increased its holdings in shares of Bristol Myers Squibb by 11.5% in the third quarter. Dimensional Fund Advisors LP now owns 18,143,672 shares of the biopharmaceutical company's stock valued at $818,105,000 after purchasing an additional 1,873,618 shares during the period. Legal &amp; General Group Plc increased its holdings in shares of Bristol Myers Squibb by 8.4% in the third quarter. Legal &amp; General Group Plc now owns 17,075,743 shares of the biopharmaceutical company's stock valued at $770,116,000 after purchasing an additional 1,317,199 shares during the period. Finally, Pzena Investment Management LLC boosted its stake in shares of Bristol Myers Squibb by 0.4% in the third quarter. Pzena Investment Management LLC now owns 14,901,604 shares of the biopharmaceutical company's stock worth $672,062,000 after buying an additional 58,129 shares during the last quarter. 76.41% of the stock is owned by institutional investors and hedge funds.</p>
<div class="lb-trans"><p>其他一些对冲基金也调整了对该公司的持股。先锋集团（Vanguard Group Inc.）在第四季度将其在百时美施贵宝的持股增加了 1.4%。先锋集团目前持有 198,727,768 股该生物制药公司的股票，价值 10,719,376,000 美元，此前在此期间额外购买了 2,743,759 股。道富银行（State Street Corp）在第三季度将其在百时美施贵宝的持股增加了 2.0%。道富银行目前持有 96,595,232 股该生物制药公司的股票，价值 4,356,445,000 美元，此前在此期间额外购买了 1,855,238 股。Dimensional Fund Advisors LP 在第三季度将其在百时美施贵宝的持股增加了 11.5%。Dimensional Fund Advisors LP 目前持有 18,143,672 股该生物制药公司的股票，价值 818,105,000 美元，此前在此期间额外购买了 1,873,618 股。Legal &amp; General Group Plc 在第三季度将其在百时美施贵宝的持股增加了 8.4%。Legal &amp; General Group Plc 目前持有 17,075,743 股该生物制药公司的股票，价值 770,116,000 美元，此前在此期间额外购买了 1,317,199 股。最后，Pzena Investment Management LLC 在第三季度将其在百时美施贵宝的持股增加了 0.4%。Pzena Investment Management LLC 目前持有 14,901,604 股该生物制药公司的股票，价值 672,062,000 美元，此前在上个季度额外购买了 58,129 股。76.41% 的股票由机构投资者和对冲基金持有。</p>
</div><h2>Analysts Set New Price Targets</h2>
<div class="lb-trans"><h2>分析师设定新的价格目标</h2>
</div><p>BMY has been the topic of a number of recent research reports. Cantor Fitzgerald upped their target price on Bristol Myers Squibb from $45.00 to $54.00 and gave the stock a &#34;neutral&#34; rating in a research note on Wednesday, April 8th. Morgan Stanley restated an &#34;underweight&#34; rating and issued a $40.00 target price on shares of Bristol Myers Squibb in a research note on Friday, February 6th. HSBC upped their target price on Bristol Myers Squibb from $53.00 to $60.00 and gave the stock a &#34;hold&#34; rating in a research note on Tuesday, March 17th. Bank of America lowered their target price on Bristol Myers Squibb from $68.00 to $67.00 and set a &#34;buy&#34; rating on the stock in a research note on Thursday, April 9th. Finally, Royal Bank Of Canada initiated coverage on Bristol Myers Squibb in a research note on Tuesday, February 24th. They issued a &#34;sector perform&#34; rating and a $60.00 target price on the stock. Eight research analysts have rated the stock with a Buy rating, ten have assigned a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat.com, the company presently has a consensus rating of &#34;Hold&#34; and an average target price of $61.31.</p>
<div class="lb-trans"><p>BMY 近期成为多份研究报告的主题。Cantor Fitzgerald 将百时美施贵宝的目标价格从 45.00 美元上调至 54.00 美元，并在 4 月 8 日的研究报告中给予该股票 “中性” 评级。摩根士丹利在 2 月 6 日的研究报告中重申了 “减持” 评级，并对百时美施贵宝的股票设定了 40.00 美元的目标价格。汇丰银行在 3 月 17 日的研究报告中将百时美施贵宝的目标价格从 53.00 美元上调至 60.00 美元，并给予该股票 “持有” 评级。美国银行在 4 月 9 日的研究报告中将百时美施贵宝的目标价格从 68.00 美元下调至 67.00 美元，并对该股票设定了 “买入” 评级。最后，加拿大皇家银行在 2 月 24 日的研究报告中开始覆盖百时美施贵宝。他们给予该股票 “行业表现” 评级，并设定了 60.00 美元的目标价格。八位研究分析师对该股票给予了买入评级，十位给予了持有评级，一位给予了卖出评级。根据 MarketBeat.com 的数据，该公司的当前共识评级为 “持有”，平均目标价格为 61.31 美元。</p>
</div><ul>
<li>Why GRAIL Stock Could Be Biotech’s Next Big Breakout</li>
</ul>
<div class="lb-trans"><ul>
<li>为什么 GRAIL 股票可能成为生物技术领域的下一个重大突破</li>
</ul>
</div><p><strong>Check Out Our Latest Stock Analysis on Bristol Myers Squibb</strong></p>
<div class="lb-trans"><p><strong>查看我们对百时美施贵宝的最新股票分析</strong></p>
</div><h2>Insider Transactions at Bristol Myers Squibb</h2>
<div class="lb-trans"><h2>百时美施贵宝的内部交易</h2>
</div><p>In other Bristol Myers Squibb news, EVP David V. Elkins sold 30,000 shares of the stock in a transaction that occurred on Wednesday, April 1st. The stock was sold at an average price of $61.67, for a total transaction of $1,850,100.00. Following the transaction, the executive vice president owned 159,248 shares in the company, valued at approximately $9,820,824.16. This represents a 15.85% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Corporate insiders own 0.05% of the company's stock.</p>
<div class="lb-trans"><p>在其他百时美施贵宝的新闻中，执行副总裁 David V. Elkins 在 4 月 1 日星期三出售了 30,000 股该股票。该股票以平均价格 61.67 美元出售，总交易额为 1,850,100.00 美元。交易后，该执行副总裁在公司持有 159,248 股，价值约为 9,820,824.16 美元。这代表了他们持股的 15.85% 的减少。该出售在向 SEC 提交的文件中披露，可以通过此超链接访问。公司内部人士持有该公司股票的 0.05%。</p>
</div><h2>Bristol Myers Squibb Stock Performance</h2>
<div class="lb-trans"><h2>百时美施贵宝股票表现</h2>
</div><ul>
<li>Don’t Be Fooled by the Bounce: The Market Storm Isn’t Over Yet</li>
</ul>
<div class="lb-trans"><ul>
<li>不要被反弹所迷惑：市场风暴尚未结束</li>
</ul>
</div><p>Shares of BMY stock opened at $56.76 on Friday. The company has a market capitalization of $115.91 billion, a P/E ratio of 15.94, a P/E/G ratio of 0.16 and a beta of 0.26. The business's 50 day moving average is $58.74 and its two-hundred day moving average is $55.34. The company has a current ratio of 1.42, a quick ratio of 1.28 and a debt-to-equity ratio of 2.10. Bristol Myers Squibb Company has a 12-month low of $42.52 and a 12-month high of $62.89.</p>
<div class="lb-trans"><p>BMY 股票在周五开盘价为 56.76 美元。该公司的市值为 1159.1 亿美元，市盈率为 15.94，市盈增长比率为 0.16，贝塔值为 0.26。该公司的 50 日移动平均线为 58.74 美元，200 日移动平均线为 55.34 美元。该公司的流动比率为 1.42，速动比率为 1.28，债务与股本比率为 2.10。百时美施贵宝公司的 12 个月低点为 42.52 美元，12 个月高点为 62.89 美元。</p>
</div><p>Bristol Myers Squibb (NYSE:BMY - Get Free Report) last issued its quarterly earnings results on Thursday, April 30th. The biopharmaceutical company reported $1.58 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $1.42 by $0.16. The company had revenue of $11.49 billion for the quarter, compared to the consensus estimate of $10.93 billion. Bristol Myers Squibb had a return on equity of 64.87% and a net margin of 15.01%.Bristol Myers Squibb's revenue for the quarter was up 2.6% on a year-over-year basis. During the same quarter in the prior year, the business posted $1.80 earnings per share. Bristol Myers Squibb has set its FY 2026 guidance at 6.050-6.350 EPS. Analysts expect that Bristol Myers Squibb Company will post 6.3 EPS for the current fiscal year.</p>
<div class="lb-trans"><p>百时美施贵宝（NYSE:BMY - 获取免费报告）最近在 4 月 30 日星期四发布了季度财报。该生物制药公司报告每股收益（EPS）为 1.58 美元，超出分析师的共识预期 1.42 美元，超出幅度为 0.16 美元。该公司在本季度的收入为 114.9 亿美元，而共识预期为 109.3 亿美元。百时美施贵宝的股本回报率为 64.87%，净利润率为 15.01%。百时美施贵宝本季度的收入同比增长 2.6%。在去年同期，该公司每股收益为 1.80 美元。百时美施贵宝已将其 2026 财年的指导目标设定为 6.050-6.350 EPS。分析师预计百时美施贵宝公司在当前财年将发布 6.3 EPS。</p>
</div><h2>Bristol Myers Squibb Announces Dividend</h2>
<div class="lb-trans"><h2>百时美施贵宝宣布分红</h2>
</div><p>The firm also recently declared a quarterly dividend, which was paid on Friday, May 1st. Shareholders of record on Thursday, April 2nd were given a dividend of $0.63 per share. The ex-dividend date was Thursday, April 2nd. This represents a $2.52 dividend on an annualized basis and a yield of 4.4%. Bristol Myers Squibb's dividend payout ratio is currently 70.79%.</p>
<div class="lb-trans"><p>该公司最近还宣布了一项季度分红，该分红于 5 月 1 日星期五支付。4 月 2 日星期四的登记股东获得每股 0.63 美元的分红。除息日期为 4 月 2 日星期四。这代表了每年 2.52 美元的分红，收益率为 4.4%。百时美施贵宝的分红支付比率目前为 70.79%。</p>
</div><h2>Bristol Myers Squibb Profile</h2>
<div class="lb-trans"><h2>百时美施贵宝简介</h2>
</div><p>(Free Report)</p>
<div class="lb-trans"><p>（免费报告）</p>
</div><p>Bristol Myers Squibb is a global biopharmaceutical company headquartered in Princeton, New Jersey, focused on discovering, developing and delivering medicines for serious diseases. The company's core activities include research and development, clinical development, manufacturing and commercialization of prescription pharmaceuticals across multiple therapeutic areas. BMS concentrates on advancing therapies in oncology, hematology, immunology, cardiovascular disease and specialty areas through both small molecules and biologics.</p>
<div class="lb-trans"><p>百时美施贵宝是一家全球生物制药公司，总部位于新泽西州普林斯顿，专注于发现、开发和提供针对严重疾病的药物。公司的核心业务包括在多个治疗领域进行处方药的研究与开发、临床开发、生产和商业化。百时美施贵宝专注于通过小分子和生物制剂推进肿瘤学、血液学、免疫学、心血管疾病和特殊领域的治疗。</p>
</div><p>BMS's marketed portfolio and late‑stage pipeline reflect a strong emphasis on cancer and immune‑mediated conditions.</p>
<div class="lb-trans"><p>百时美施贵宝的市场产品组合和后期管线反映出对癌症和免疫介导疾病的强烈关注。</p>
</div><h2>Read More</h2>
<div class="lb-trans"><h2>了解更多</h2>
</div><ul>
<li>Five stocks we like better than Bristol Myers Squibb</li>
<li>YETI Rallies After Earnings Beat and Raised Outlook</li>
<li>How the 3 Leading Quantum Firms Stack Up After Q1 Earnings</li>
<li>Cisco’s Vertical Rally May Still Be in the Early Innings</li>
<li>Amazon vs. Alibaba: One Is Clearly The Better Value Play right Now</li>
</ul>
<div class="lb-trans"><ul>
<li>五只我们认为比百时美施贵宝更好的股票</li>
<li>YETI 在财报超预期和上调前景后反弹</li>
<li>三家领先量子公司的第一季度财报对比</li>
<li>思科的垂直反弹可能仍处于早期阶段</li>
<li>亚马逊与阿里巴巴：现在显然更具价值的选择</li>
</ul>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5ZU0UmU3ltYm9sPUJNWQ" alt="" original-src="https://www.marketbeat.com/scripts/SECFilingChart.ashx?Prefix=NYSE&amp;Symbol=BMY"/></p>
<p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即时新闻提醒由叙事科学技术和来自 MarketBeat 的金融数据生成，以便为读者提供最快的报道和公正的覆盖。请将有关此故事的任何问题或评论发送至 contact@marketbeat.com。</em></p>
</div><h2>Should You Invest $1,000 in Bristol Myers Squibb Right Now?</h2>
<div class="lb-trans"><h2>你现在应该投资 1,000 美元在百时美施贵宝吗？</h2>
</div><p>Before you consider Bristol Myers Squibb, you'll want to hear this.</p>
<div class="lb-trans"><p>在考虑百时美施贵宝之前，你需要听听这个。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Bristol Myers Squibb wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已识别出五只顶级分析师悄悄建议客户现在购买的股票，以便在更广泛的市场注意到之前……而百时美施贵宝并不在名单上。</p>
</div><p>While Bristol Myers Squibb currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>虽然百时美施贵宝目前在分析师中被评为持有评级，但顶级分析师认为这五只股票更值得购买。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>在这里查看这五只股票</p>
</div>

Bristol Myers Squibb Company $BMY Shares Acquired by Allworth Financial LP

Market Beat

道富银行

Legal & General Group Plc

摩根士丹利

汇丰控股有限公司

汇丰

汇丰控股

美国银行

加拿大皇家银行

GRAIL

Bristol-Myers Squibb Company

State Street® US Equity Premium Inc ETF

MORGAN STANLEY DEP SHS EA REP 1/1000 SHS NON CUM PFD O

MORGAN STANLEY DEP SHS REPSTG 1/1000TH PFD SER Q

MORGAN STANLEY DEP SHS REPS 1/1000 7.125% PFD E

MORGAN STANLEY NON-CUM DEP SH REP 1/1000 PFD SER I

MORGAN STANLEY 4.875 DEP SHS REP 1/1000 NCUM PFD SR L

MORGAN STANLEY 6.5%DEP SHS REPSTG 1/1000 NON CUM SER P

MORGAN STANLEY DEP SHS REPS 1/1000 PFD SER 'A'

MORGAN STANLEY DEP SHS REPR 1/1000TH INT PFD SER 'F' FX

MORGAN STANLEY DEP SHS REP 1/1000 NON-CUM PFD STK SER K

HSBC 5xShortSG241213

BANK OF AMERICA CORPORATION DEP SHS REP 1/1000TH INT NON CUM PFD QQ

BANK OF AMERICA CORPORATION DEP SHS REP 1/1200TH PRF SERIES '5'

BANK OF AMERICA CORPORATION 7.25% NON-CUM PERP CONV PFD SER L

BANK OF AMERICA CORPORATION 5.875%NON CUM DEP SHS REP1/1000TH SER HH

BANK OF AMERICA CORPORATION DEP SHS REP 1/1200TH PRF SERIES '2'

BANK OF AMERICA CORPORATION 5% DEP SHS REPR 1/1000TH NON CUM PFD LL

BANK OF AMERICA CORPORATION DEP SHARES REP 1/1000TH PERP PFD SER 'E'

BANK OF AMERICA CORPORATION INCOME CAPITAL OBLIG NTS DUE 15/12/2066

BANK OF AMERICA CORPORATION 4.375% DP SH RP 1/1000TH IN NON CU PF NN

BANK OF AMERICA CORPORATION DEP SH REP 1/1200TH PRF SER 1 USD25

BANK OF AMERICA CORPORATION 5.375%DEP SHS REP 1/1000TH NON CUM SR KK

BANK OF AMERICA CORPORATION 6%NON CUM DEP SHS EACH REP 1/1000 SER GG

BANK OF AMERICA CORPORATION DEP SHS REP 1/1200 PFD SER 4 USD25

BANK OF AMERICA CORPORATION DEP SHS REP 1/1000TH NON CUM PFD SER SS

BANK OF AMERICA CORPORATION 4.125%DEP SH REP 1/1000 PFD SER PP USD25

Bank of America Corp

Allworth Financial LP 收购了百时美施贵宝公司 $BMY 的股票